The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 30, 2007
Filed:
Jun. 21, 2000
William Alexander Denny, Pakuranga, NZ;
Gordon William Rewcastle, Manurewa, NZ;
Ellen Dobrusin, Ann Arbor, MI (US);
James Bernard Kramer, Sylvania, OH (US);
Dennis Joseph Mcnamara, Ann Arbor, MI (US);
Howard Daniel Hollis Showalter, Ann Arbor, MI (US);
Peter Laurence Toogood, Ann Arbor, MI (US);
William Alexander Denny, Pakuranga, NZ;
Gordon William Rewcastle, Manurewa, NZ;
Ellen Dobrusin, Ann Arbor, MI (US);
James Bernard Kramer, Sylvania, OH (US);
Dennis Joseph McNamara, Ann Arbor, MI (US);
Howard Daniel Hollis Showalter, Ann Arbor, MI (US);
Peter Laurence Toogood, Ann Arbor, MI (US);
Warner-Lambert Company, Morris Plains, NJ (US);
Abstract
Disclosed are compounds of Formulae (Ia), (Ib), (Ic), (Id) wherein: W is NH, S, SO, or SO; Ris (un)substituted aryl, (un)substituted heteroaryl, or (un)substituted carbocycle or heterocycle; Q is hydrogen or lower alkyl; Rand Rare the same or different and represent hydrogen, halogen, lower alkyl, lower alkoxy, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl; and Ris hydrogen, lower alkyl or an (un)substituted carbocyclic group containing from 3–7 members, up to two of which members are optionally hetero atoms selected from oxygen and nitrogen; or Ris (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl. These compounds are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).